Tuesday, January 19, 2016

"Safe Nowhere" - An Exciting New Venture!

My latest novel Safe Nowhere, a
fictional account of the clashing of a brilliant and quirky new lawyer, Katie
Hornsby, with a powerful and crooked drug company and its deadly foreign
generic drug, will be released near the
end of February in print and e-book formats on Amazon, I-Books,
Barnes and Noble and other major sellers. The story
line of Safe Nowhere follows the pattern of my previous novels in presenting timely issues
of safety and corporate wrongdoing within the pharmaceutical industry and the book specifically addresses the lack of quality and purity of foreign generic drugs that are currently flooding the American marketplace. Katie Hornsby faces obstacle after obstacle in her fight to help her clients. A powerful combination of interests stack the deck against her quest.While Safe Nowhere is a work of fiction, it is written within the context of present-day reality. More than 83% of all U.S. prescriptions written in the United States are filled today with generic drugs. India’s generic drug industry is the source of more than forty per cent (40%) of our generic drug supply and routinely violates basic quality control standards and knowingly exports sub-par medicines. The Drug Controller General of India, G N Singh, recently offered an alarmingexcusefor the transgressions of India’s generic makers, “Our society and our economy are different from those in the US. If I have to follow US standards in inspecting facilities supplying to the Indian market, we will have to shut almost all of those. We are not the US, the infrastructure and resources available there are much different from those in our country.” If you are taking a generic drug, it is highly probable that you are one of millions of guinea pigs being unknowingly exposed to an ongoing crap-shoot-like experiment on the safety of these foreign products.

According to theFDAthere
are 526 drug manufacturing plants in India making products for the U.S. market.
The agency has 10 investigators, soon to increase to only 19, to cover the
entire country. China, as another example, has 517 drug manufacturing plants making products that
will end up in the U.S. market. At last count there were three investigators
for the entire country. Other
countries have had problems as well.It was recentlyreported that, “The US Food and
Drug Administration found that foreign producers of drugs were
increasingly falsifying data about the quality of medicines, and . .
. issued six warning letters to companies in Mexico, Poland, the United Arab
Emirates, India, and Canada about the quality of active pharmaceutical
ingredients, over-the-counter solutions, and injectables.*

Under the rubric of “transparency,” the FDA has claimed on itswebsitein the past that “foreign drug manufacturing plants are routinely
inspected for compliance with applicable regulations, including the Current
Good Manufacturing Practices.” andthat
the “agency ensured that generic makers adhered to proper manufacturing
standards and ‘the entire generic industry should not be judged by a few
isolated incidents'.”This rose-colored
myopia is not borne out by reality. A more realistic assessment of
the FDA’s current ability to do its job correctly is found buried deep in the
FDA’s latestGlobal Assessment
Program reportthat
tells the alarming truth; “Because of the vast and growing number of foreign
facilities, FDA does not have—nor will it—the resources to directly
inspect all the higher-priority facilities at desired frequencies.” and
“Inspections still account for only a small fraction of the more than 300,000
foreign facilities manufacturing or processing FDA-regulated products for
the U.S. market." The danger potential is growing geometrically.Importsof
foreign-made drugs increased by nearly five-fold from 2007 to 2013 and India
and China, the leaders of the pack, expect more than 400 per cent increases in
their product exports by 2020.